Patients with liver cirrhosis will be randomised to one of three trial groups: group 1: Control group, Standard conservative management; group 2 treatment: granulocyte colony-stimulating factor (G-CSF; lenograstim) 15 μg/kg body weight daily on days 1–5; group 3 treatment: G-CSF 15 μg/kg body weight daily on days 1–5 followed by leukapheresis, isolation and aliquoting of CD133+ cells. The gene discussed is CSF3; the disease is cirrhosis of liver.